Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic (NYSE:MDT) announced two milestones for the Affera Sphere-360 pulsed field ablation (PFA) catheter: CE Mark in Europe and completion of first cases in the U.S. Horizon 360 IDE pivotal trial on Jan 23, 2026. The Sphere-360 is a rotation-free, all-in-one mapping and single-shot PFA catheter that adapts to pulmonary vein anatomy, provides real-time local impedance, and integrates with the Affera mapping and ablation system. A prospective European single-arm study presented one-year data showing efficacy, safety, and durability that supported CE Mark. The Horizon 360 IDE will evaluate safety and effectiveness for treating paroxysmal atrial fibrillation in U.S. centers.
Medtronic (NYSE: MDT) announced FDA 510(k) clearance of the MiniMed Go™ app and Smart MDI system on January 12, 2026. The system links the InPen smart insulin pen with Abbott's Instinct sensor to provide real-time glucose data, dose calculations, missed-dose alerts, and CareLink reporting. Cleared for insulin-requiring type 1 and type 2 diabetes ages 7+, and ages 2–6 under caregiver supervision. Commercial launch in the U.S. is expected in spring 2026. Compatibility of Simplera sensor remains under FDA review.
Medtronic (MDT) announced a real-world retrospective analysis (CareLink data, Jan 2, 2020–Mar 31, 2025) showing MiniMed 780G users achieved ADA-recommended time-in-range (TIR) goals even on days when mealtime boluses were missed.
Key results: 76.3% TIR on missed-bolus days with recommended optimal settings (100 mg/dL target; 2-hour active insulin time) vs 69.3% TIR for other settings; mean sensor glucose 149 mg/dL vs 160 mg/dL; GMI 6.9% vs 7.1%; >61% met all three ADA targets vs 36.6%.
Study used N=369,467 users (No Bolus cohort N=54,553); deliberate no-bolus is off-label and not recommended.
Medtronic (NYSE: MDT) announced that Chairman and CEO Geoff Martha will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 starting at 10:30 a.m. PST (12:30 p.m. CST). Martha will deliver a formal presentation and take questions, followed by a Q&A session with EVP and CFO Thierry Piéton.
A live webcast and an archive will be available the same day via the Events link on the company's investor relations website.
Medtronic (NYSE: MDT) announced that its Diabetes business, to be named MiniMed, filed a registration statement on Form S-1 with the U.S. SEC on Dec. 19, 2025 for a proposed initial public offering of newly issued common stock.
MiniMed said it intends to list on the Nasdaq Global Select Market under the symbol MMED, prefers a path of an IPO followed by a split-off, and expects the offering to commence after SEC review and subject to market conditions. The number of shares and price range are not yet determined. Securities may not be sold until the registration becomes effective.
Goldman Sachs, BofA Securities, Citigroup and Morgan Stanley are the active bookrunners; several banks will act as joint bookrunning managers and co-managers.
Medtronic (NYSE: MDT) announced a $0.71 per share cash dividend for Q3 of fiscal 2026. The board approved the dividend on December 4, 2025, payable on January 16, 2026 to shareholders of record at the close of business on December 26, 2025.
This declaration is consistent with the company's May 2025 dividend increase and continues Medtronic's track record as a S&P 500 Dividend Aristocrat, having raised its annual dividend for 48 consecutive years.
Medtronic (NYSE: MDT) announced FDA clearance of the Hugo™ robotic-assisted surgery (RAS) system for use in minimally invasive urologic procedures including prostatectomy, nephrectomy, and cystectomy.
The release notes the Expand URO IDE study—described as the largest US multi-port robotic urology trial—met primary safety and effectiveness endpoints, and estimates those urologic procedures total about 230,000 surgeries per year in the U.S. Medtronic plans a purposeful U.S. launch with broader specialty indications expected later.
Medtronic (NYSE: MDT) announced the U.S. commercial launch of the MiniMed 780G system integrated with the Instinct sensor, made by Abbott, on Dec 2, 2025. The system received U.S. FDA clearance earlier in 2025 to enable integration with Instinct and is now shipping nationwide.
The Instinct sensor offers up to 15 days wear and is described as the world's smallest and thinnest integrated CGM; when paired with MiniMed 780G it provides real-time glucose readings and automates insulin adjustments every 5 minutes.
Medtronic (NYSE: MDT) reported Q2 FY26 revenue of $8.96B, up 6.6% reported and 5.5% organic, and GAAP diluted EPS of $1.07 (+8%). Non-GAAP diluted EPS was $1.36 (+8%).
Highlights include Cardiac Ablation Solutions +71% (PFA portfolio), Cardiovascular revenue $3.436B (+10.8%), Diabetes revenue $757M (+10.3%), and several regulatory/coverage wins (CMS NCD for Symplicity, FDA approvals for Altaviva and MiniMed 780G updates).
The company raised FY26 guidance to ~5.5% organic revenue growth and $5.62–$5.66 adjusted EPS; tariffs could reduce results by about $185M.
Medtronic (NYSE: MDT) will report second-quarter fiscal 2026 results on Tuesday, November 18, 2025, covering the quarter ended October 24, 2025. A summary news release will be issued at approximately 5:45 a.m. CST at https://news.medtronic.com and a video webcast discussing results will begin at 7:00 a.m. CST at https://investorrelations.medtronic.com.
A replay and transcript of prepared remarks will be available within 24 hours via the Events link on the investor site. Medtronic also plans to report FY2026 Q3 results on February 17, 2026 and Q4 results on May 20, 2026, with confirmations to follow. Medtronic is a global healthcare technology company headquartered in Galway with more than 95,000 employees and technologies treating 70 health conditions.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
